| # | Title | Journal | Year | Citations |
|---|
|
| 1 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers | JAMA - Journal of the American Medical Association | 2017 | 2,039 |
| 2 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Lancet, The | 2014 | 1,881 |
| 3 | Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders | Nature Reviews Drug Discovery | 2014 | 1,312 |
| 4 | Whole–genome characterization of chemoresistant ovarian cancer | Nature | 2015 | 1,263 |
| 5 | Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study | Lancet, The | 2020 | 1,237 |
| 6 | Cancer Stem Cells: Current Status and Evolving Complexities | Cell Stem Cell | 2012 | 1,145 |
| 7 | Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Science Translational Medicine | 2016 | 1,086 |
| 8 | PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma | New England Journal of Medicine | 2018 | 1,072 |
| 9 | Translational biology of osteosarcoma | Nature Reviews Cancer | 2014 | 1,000 |
| 10 | Perforin and granzymes: function, dysfunction and human pathology | Nature Reviews Immunology | 2015 | 941 |
| 11 | [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study | Lancet Oncology, The | 2018 | 872 |
| 12 | Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients | Oncotarget | 2016 | 842 |
| 13 | Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Blood | 2009 | 832 |
| 14 | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2019 | 813 |
| 15 | Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis | Nature Medicine | 2018 | 731 |
| 16 | Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia | New England Journal of Medicine | 2018 | 722 |
| 17 | Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02 | Journal of Clinical Oncology | 2010 | 698 |
| 18 | CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity | Nature | 2017 | 674 |
| 19 | Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis | European Urology | 2020 | 658 |
| 20 | Lymphangiogenesis and lymphatic vessel remodelling in cancer | Nature Reviews Cancer | 2014 | 650 |
| 21 | [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial | Lancet, The | 2021 | 629 |
| 22 | Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells | Clinical Cancer Research | 2013 | 612 |
| 23 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors | Advances in Anatomic Pathology | 2017 | 576 |
| 24 | TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS | Cell | 2020 | 545 |
| 25 | Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02 | Journal of Clinical Oncology | 2006 | 533 |
| 26 | Immunohistochemistry Versus Microsatellite Instability Testing in Phenotyping Colorectal Tumors | Journal of Clinical Oncology | 2002 | 531 |
| 27 | Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer | Annals of Oncology | 2015 | 531 |
| 28 | RIPK1 Regulates RIPK3-MLKL-Driven Systemic Inflammation and Emergency Hematopoiesis | Cell | 2014 | 510 |
| 29 | The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant | Cancer Treatment Reviews | 2015 | 501 |
| 30 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research | Advances in Anatomic Pathology | 2017 | 501 |
| 31 | Radiotherapy toxicity | Nature Reviews Disease Primers | 2019 | 497 |
| 32 | Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers | Journal of Medical Genetics | 2015 | 488 |
| 33 | Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53 | Cancer Cell | 2012 | 479 |
| 34 | Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer | New England Journal of Medicine | 2018 | 475 |
| 35 | Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study | Lancet, The | 2019 | 471 |
| 36 | Structures of the HIN Domain:DNA Complexes Reveal Ligand Binding and Activation Mechanisms of the AIM2 Inflammasome and IFI16 Receptor | Immunity | 2012 | 470 |
| 37 | Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape | European Journal of Cancer | 2017 | 465 |
| 38 | Key steps for effective breast cancer prevention | Nature Reviews Cancer | 2020 | 465 |
| 39 | Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers | Proceedings of the National Academy of Sciences of the United States of America | 2017 | 463 |
| 40 | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial | Lancet, The | 2017 | 461 |
| 41 | Consensus guidelines for the use and interpretation of angiogenesis assays | Angiogenesis | 2018 | 457 |
| 42 | BET inhibitor resistance emerges from leukaemia stem cells | Nature | 2015 | 455 |
| 43 | Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy | PLoS Pathogens | 2014 | 446 |
| 44 | In situ identification of bipotent stem cells in the mammary gland | Nature | 2014 | 446 |
| 45 | RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors | Clinical Cancer Research | 2016 | 439 |
| 46 | Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer | New England Journal of Medicine | 2022 | 436 |
| 47 | Intratumoral heterogeneity in cancer progression and response to immunotherapy | Nature Medicine | 2021 | 433 |
| 48 | Gene-engineered T cells for cancer therapy | Nature Reviews Cancer | 2013 | 430 |
| 49 | The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions | Nature Immunology | 2014 | 421 |
| 50 | Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial | Lancet Oncology, The | 2019 | 421 |
